BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer

Shinsuke Nakashima, Shogo Kobayashi, Hiroaki Nagano, Akira Tomokuni, Yoshito Tomimaru, Tadafumi Asaoka, Naoki Hama, Hiroshi Wada, Koichi Kawamoto, Shigeru Marubashi, Hidetoshi Eguchi, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The BRCA/Fanconi anemia (FA) pathway plays a key role in the repair of DNA double strand breaks. We focused on this pathway to clarify chemoresistance mechanisms in biliary tract cancer (BTC). We also investigated changes in the CD24+/44+ population that may be involved in chemoresistance, as this population likely includes cancer stem cells. We used three BTC cell lines to establish gemcitabine (GEM)-resistant (GR) cells and evaluated the expression of BRCA/FA pathway components, chemoresistance, and the effect of BRCA/FA pathway inhibition on the CD24+/44+ population. FANCD2 and CD24 expression were evaluated in 108 resected BTC specimens. GR cells highly expressed the BRCA/FA components. The BRCA/FA pathway was upregulated by GEM and cisplatin (CDDP) exposure. Inhibition using siRNA and RAD51 inhibitor sensitized GR cells to GEM or CDDP. The CD24+/44+ population was increased in GR and parent BTC cells treated with GEM or CDDP and highly expressed BRCA/FA genes. FANCD2 was related to CD24 expression in resected BTC specimens. Inhibition of the BRCA/FA pathway under GEM reduced the CD24+/44+ population in MzChA1-GR cells. Thus, high expression of the BRCA/FA pathway is one mechanism of chemoresistance against GEM and/or CDDP and is related to the CD24+/44+ population in BTC.

Original languageEnglish
Pages (from-to)584-591
Number of pages8
JournalCancer Science
Volume106
Issue number5
DOIs
Publication statusPublished - May 1 2015

Fingerprint

gemcitabine
Biliary Tract Neoplasms
Fanconi Anemia
Population
Double-Stranded DNA Breaks
Neoplastic Stem Cells
Small Interfering RNA
Cisplatin

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Nakashima, S., Kobayashi, S., Nagano, H., Tomokuni, A., Tomimaru, Y., Asaoka, T., ... Mori, M. (2015). BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer. Cancer Science, 106(5), 584-591. https://doi.org/10.1111/cas.12652

BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer. / Nakashima, Shinsuke; Kobayashi, Shogo; Nagano, Hiroaki; Tomokuni, Akira; Tomimaru, Yoshito; Asaoka, Tadafumi; Hama, Naoki; Wada, Hiroshi; Kawamoto, Koichi; Marubashi, Shigeru; Eguchi, Hidetoshi; Doki, Yuichiro; Mori, Masaki.

In: Cancer Science, Vol. 106, No. 5, 01.05.2015, p. 584-591.

Research output: Contribution to journalArticle

Nakashima, S, Kobayashi, S, Nagano, H, Tomokuni, A, Tomimaru, Y, Asaoka, T, Hama, N, Wada, H, Kawamoto, K, Marubashi, S, Eguchi, H, Doki, Y & Mori, M 2015, 'BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer', Cancer Science, vol. 106, no. 5, pp. 584-591. https://doi.org/10.1111/cas.12652
Nakashima S, Kobayashi S, Nagano H, Tomokuni A, Tomimaru Y, Asaoka T et al. BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer. Cancer Science. 2015 May 1;106(5):584-591. https://doi.org/10.1111/cas.12652
Nakashima, Shinsuke ; Kobayashi, Shogo ; Nagano, Hiroaki ; Tomokuni, Akira ; Tomimaru, Yoshito ; Asaoka, Tadafumi ; Hama, Naoki ; Wada, Hiroshi ; Kawamoto, Koichi ; Marubashi, Shigeru ; Eguchi, Hidetoshi ; Doki, Yuichiro ; Mori, Masaki. / BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer. In: Cancer Science. 2015 ; Vol. 106, No. 5. pp. 584-591.
@article{613dc0fea93b4b3ca3033411c3b3ba74,
title = "BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer",
abstract = "The BRCA/Fanconi anemia (FA) pathway plays a key role in the repair of DNA double strand breaks. We focused on this pathway to clarify chemoresistance mechanisms in biliary tract cancer (BTC). We also investigated changes in the CD24+/44+ population that may be involved in chemoresistance, as this population likely includes cancer stem cells. We used three BTC cell lines to establish gemcitabine (GEM)-resistant (GR) cells and evaluated the expression of BRCA/FA pathway components, chemoresistance, and the effect of BRCA/FA pathway inhibition on the CD24+/44+ population. FANCD2 and CD24 expression were evaluated in 108 resected BTC specimens. GR cells highly expressed the BRCA/FA components. The BRCA/FA pathway was upregulated by GEM and cisplatin (CDDP) exposure. Inhibition using siRNA and RAD51 inhibitor sensitized GR cells to GEM or CDDP. The CD24+/44+ population was increased in GR and parent BTC cells treated with GEM or CDDP and highly expressed BRCA/FA genes. FANCD2 was related to CD24 expression in resected BTC specimens. Inhibition of the BRCA/FA pathway under GEM reduced the CD24+/44+ population in MzChA1-GR cells. Thus, high expression of the BRCA/FA pathway is one mechanism of chemoresistance against GEM and/or CDDP and is related to the CD24+/44+ population in BTC.",
author = "Shinsuke Nakashima and Shogo Kobayashi and Hiroaki Nagano and Akira Tomokuni and Yoshito Tomimaru and Tadafumi Asaoka and Naoki Hama and Hiroshi Wada and Koichi Kawamoto and Shigeru Marubashi and Hidetoshi Eguchi and Yuichiro Doki and Masaki Mori",
year = "2015",
month = "5",
day = "1",
doi = "10.1111/cas.12652",
language = "English",
volume = "106",
pages = "584--591",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer

AU - Nakashima, Shinsuke

AU - Kobayashi, Shogo

AU - Nagano, Hiroaki

AU - Tomokuni, Akira

AU - Tomimaru, Yoshito

AU - Asaoka, Tadafumi

AU - Hama, Naoki

AU - Wada, Hiroshi

AU - Kawamoto, Koichi

AU - Marubashi, Shigeru

AU - Eguchi, Hidetoshi

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2015/5/1

Y1 - 2015/5/1

N2 - The BRCA/Fanconi anemia (FA) pathway plays a key role in the repair of DNA double strand breaks. We focused on this pathway to clarify chemoresistance mechanisms in biliary tract cancer (BTC). We also investigated changes in the CD24+/44+ population that may be involved in chemoresistance, as this population likely includes cancer stem cells. We used three BTC cell lines to establish gemcitabine (GEM)-resistant (GR) cells and evaluated the expression of BRCA/FA pathway components, chemoresistance, and the effect of BRCA/FA pathway inhibition on the CD24+/44+ population. FANCD2 and CD24 expression were evaluated in 108 resected BTC specimens. GR cells highly expressed the BRCA/FA components. The BRCA/FA pathway was upregulated by GEM and cisplatin (CDDP) exposure. Inhibition using siRNA and RAD51 inhibitor sensitized GR cells to GEM or CDDP. The CD24+/44+ population was increased in GR and parent BTC cells treated with GEM or CDDP and highly expressed BRCA/FA genes. FANCD2 was related to CD24 expression in resected BTC specimens. Inhibition of the BRCA/FA pathway under GEM reduced the CD24+/44+ population in MzChA1-GR cells. Thus, high expression of the BRCA/FA pathway is one mechanism of chemoresistance against GEM and/or CDDP and is related to the CD24+/44+ population in BTC.

AB - The BRCA/Fanconi anemia (FA) pathway plays a key role in the repair of DNA double strand breaks. We focused on this pathway to clarify chemoresistance mechanisms in biliary tract cancer (BTC). We also investigated changes in the CD24+/44+ population that may be involved in chemoresistance, as this population likely includes cancer stem cells. We used three BTC cell lines to establish gemcitabine (GEM)-resistant (GR) cells and evaluated the expression of BRCA/FA pathway components, chemoresistance, and the effect of BRCA/FA pathway inhibition on the CD24+/44+ population. FANCD2 and CD24 expression were evaluated in 108 resected BTC specimens. GR cells highly expressed the BRCA/FA components. The BRCA/FA pathway was upregulated by GEM and cisplatin (CDDP) exposure. Inhibition using siRNA and RAD51 inhibitor sensitized GR cells to GEM or CDDP. The CD24+/44+ population was increased in GR and parent BTC cells treated with GEM or CDDP and highly expressed BRCA/FA genes. FANCD2 was related to CD24 expression in resected BTC specimens. Inhibition of the BRCA/FA pathway under GEM reduced the CD24+/44+ population in MzChA1-GR cells. Thus, high expression of the BRCA/FA pathway is one mechanism of chemoresistance against GEM and/or CDDP and is related to the CD24+/44+ population in BTC.

UR - http://www.scopus.com/inward/record.url?scp=84929711646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929711646&partnerID=8YFLogxK

U2 - 10.1111/cas.12652

DO - 10.1111/cas.12652

M3 - Article

C2 - 25736055

AN - SCOPUS:84929711646

VL - 106

SP - 584

EP - 591

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 5

ER -